Search for more clinical trials
Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers
Conditions
Gastric Cancer - Colorectal Cancer and Pre-cancer Polyps - Pancreatic Cancer
Conditions: official terms
Pancreatic Neoplasms
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Case Control, Time Perspective: Cross-Sectional
Intervention
Name: Salivary samples
Type: Other
Overall Status
Not yet recruiting
Summary
Colorectal cancers account for 783,000 new cases and cause 437,000 deaths per year across the world. Diagnosis in the early stages improves survival rates. Up to now, these cancers are mostly diagnosed only at later stages of the disease's course through histoimmune staining and molecular biology processes on the tissues biopsied from the gastrointestinal system under invasive diagnostic procedures of colonoscopy.
Oral fluid presents a large protein complexity and has been recently used as a diagnostic biofluid for oral, as well as systematic diseases. Using oral fluid as a bio-marker for the colorectal cancer can be advantageous as it contains gastrointestinal fluids, in addition to bacteria and bacteria lysate, which can also serve as a bio-markers' source for colorectal cancers. Proteomic technologies provide the tools needed to discover and identify disease-associated biomarkers.
The aim of the present study is to identify salivary bio-markers in patients suffering from colorectal cancers.
Oral fluid presents a large protein complexity and has been recently used as a diagnostic biofluid for oral, as well as systematic diseases. Using oral fluid as a bio-marker for the colorectal cancer can be advantageous as it contains gastrointestinal fluids, in addition to bacteria and bacteria lysate, which can also serve as a bio-markers' source for colorectal cancers. Proteomic technologies provide the tools needed to discover and identify disease-associated biomarkers.
The aim of the present study is to identify salivary bio-markers in patients suffering from colorectal cancers.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:
- Has not yet started treatment for the identified cancer
Exclusion Criteria:
- medically compromised patients
- congenital syndromes
- being treated with radiotherapy or chemotherapy.
- Has not yet started treatment for the identified cancer
Exclusion Criteria:
- medically compromised patients
- congenital syndromes
- being treated with radiotherapy or chemotherapy.
Location
Hadassah Medical Organization
Jerusalem, Israel
Status: Not yet recruiting
Contact: Hadas Lemberg, PhD - 0097226777572 - lhadas@hadassah.org.il
Start Date
September 2012
Sponsors
Hadassah Medical Organization
Source
Hadassah Medical Organization
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page